Market revenue in 2023 | USD 134.3 million |
Market revenue in 2030 | USD 235.5 million |
Growth rate | 8.4% (CAGR from 2023 to 2030) |
Largest segment | Phase ii |
Fastest growing segment | Phase II |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 55.4% in 2023. Horizon Databook has segmented the South Africa cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
The South African market is expected to witness growth owing to presence of well-established infrastructure, diverse population, availability of experts, formation of separate drug regulatory agency, and easy patient recruitment. South Africa was once a commonly considered country for clinical research, but its popularity generated bottlenecks in the country's previously built regulatory structure.
The South African government overhauled its whole regulatory environment, establishing SAHPRA to oversee clinical trial evaluation and approval as well as medicinal approvals Cell and gene therapy clinical trials are outsourced to South Africa as a result of easy availability of subjects as a large number of people are suffering from HIV/AIDS.
There are around 5.6 million people in Africa suffering from HIV out of which only 2.5 million have access to drugs. There are more than 2000 cell and gene therapy clinical trials registered on ClinicalTrails.gov. The majority of the registered trials are for HIV and Tuberculosis. This has accelerated outsourcing to South Africa by international players.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa cell and gene therapy clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into South Africa cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account